photo of A/Prof David Godler

A/Prof David Godler

A/Prof David Godler

Details

Role Group Leader / Senior Research Fellow
Research area Genetics

Contact

Available for student supervision
Dr Godler is an Associate Professor at the University of Melbourne, and group leader of Diagnosis and Development Laboratory at the Murdoch Children’s Research Institute (MCRI). He has completed my PhD in 2007 at the Department of Medicine, Monash University in genetics and immunology, then undertook post-doctoral studies on epigenetic disorders associated with chromosomal abnormalities and developmental delay in the laboratory of Professor Andy Choo. He was later appointed senior postdoctoral fellow at the Victorian Clinical Genetics Services (VCGS) and MCRI. His productivity, track record and upward trajectory (15 years post PhD) is evidenced by 57 publications; 39 as 1st or last author; 81.5% in the top 10% of all journals in the medical sciences field), in such quality journals as Genet Med (X4), Clin Chem (X3), Neurol (X2), JAMA Neurol (X1), JAMA Netw Open (X1) and Mol Autism (X1) (most as a first or senior author).
He has demonstrated strong evidence of innovation and research translation, being named as an inventor on 6 patent families (with more than 40 patent filings), including 16 granted patents, related to different components of the technology developed for different diagnostic and screening applications. To date his group has: 1. Implemented a novel droplet digital PCR (ddPCR) method through VCGS for bone marrow transplantation monitoring at the Royal Children’s Hospital; 2. Developed a new diagnostic technology platform called CINQ ddPCR for an improved method of detection of low-level mosaicism in different paediatric disorders. 3. Performed successful international trials of the MS-QMA high-throughput DNA methylation screening technology for improved diagnosis of fragile X syndrome and imprinting disorders, with test implementation in the U.S.A. in collaboration with a number of commercial partners (Hensel et al. Godler 2019 Sci Rep). He has pioneered many aspects of fragile X syndrome and chromosome 15 imprinting disorders as part of previous rare disease cohort studies and also headed one the world’s largest prevalence study for FXS and chromosome 15 imprinting disorders, and related health economics studies providing evidence for the expansion of current newborn screening. In 2018, he was awarded a Next Generation Clinical Researchers Program - Career Development Fellowship, focusing on improved diagnosis, natural history studies and clinical trials for neurodevelopmental disorders associated with intellectual disability and autism. In 2020 he established and currently lead the Australian first Chromosome 15 imprinting Disorders national biobank located at MCRI. In 2022 he was awarded funding for a 5-year program from the Genomics Health Futures Mission, the Medical Research Future Fund. This program will assess benefits of extended genomic newborn screening workflow developed by his group on 100,000 infants from $55 million funded whole-of-state birth cohort called Generation Victoria. Based on this track-record he has been recognized by Expertscape to be in the top 1% of scholars globally publishing on topics related to intellectual disability over the past 10 years.
Dr Godler is an Associate Professor at the University of Melbourne, and group leader of Diagnosis and Development Laboratory at the Murdoch Children’s Research Institute (MCRI). He has completed my PhD in 2007 at the Department of Medicine, Monash...
Dr Godler is an Associate Professor at the University of Melbourne, and group leader of Diagnosis and Development Laboratory at the Murdoch Children’s Research Institute (MCRI). He has completed my PhD in 2007 at the Department of Medicine, Monash University in genetics and immunology, then undertook post-doctoral studies on epigenetic disorders associated with chromosomal abnormalities and developmental delay in the laboratory of Professor Andy Choo. He was later appointed senior postdoctoral fellow at the Victorian Clinical Genetics Services (VCGS) and MCRI. His productivity, track record and upward trajectory (15 years post PhD) is evidenced by 57 publications; 39 as 1st or last author; 81.5% in the top 10% of all journals in the medical sciences field), in such quality journals as Genet Med (X4), Clin Chem (X3), Neurol (X2), JAMA Neurol (X1), JAMA Netw Open (X1) and Mol Autism (X1) (most as a first or senior author).
He has demonstrated strong evidence of innovation and research translation, being named as an inventor on 6 patent families (with more than 40 patent filings), including 16 granted patents, related to different components of the technology developed for different diagnostic and screening applications. To date his group has: 1. Implemented a novel droplet digital PCR (ddPCR) method through VCGS for bone marrow transplantation monitoring at the Royal Children’s Hospital; 2. Developed a new diagnostic technology platform called CINQ ddPCR for an improved method of detection of low-level mosaicism in different paediatric disorders. 3. Performed successful international trials of the MS-QMA high-throughput DNA methylation screening technology for improved diagnosis of fragile X syndrome and imprinting disorders, with test implementation in the U.S.A. in collaboration with a number of commercial partners (Hensel et al. Godler 2019 Sci Rep). He has pioneered many aspects of fragile X syndrome and chromosome 15 imprinting disorders as part of previous rare disease cohort studies and also headed one the world’s largest prevalence study for FXS and chromosome 15 imprinting disorders, and related health economics studies providing evidence for the expansion of current newborn screening. In 2018, he was awarded a Next Generation Clinical Researchers Program - Career Development Fellowship, focusing on improved diagnosis, natural history studies and clinical trials for neurodevelopmental disorders associated with intellectual disability and autism. In 2020 he established and currently lead the Australian first Chromosome 15 imprinting Disorders national biobank located at MCRI. In 2022 he was awarded funding for a 5-year program from the Genomics Health Futures Mission, the Medical Research Future Fund. This program will assess benefits of extended genomic newborn screening workflow developed by his group on 100,000 infants from $55 million funded whole-of-state birth cohort called Generation Victoria. Based on this track-record he has been recognized by Expertscape to be in the top 1% of scholars globally publishing on topics related to intellectual disability over the past 10 years.

Top Publications

  • Arpone, M, Bretherton, L, Amor, D, Hearps, S, Rogers, C, Field, M, Hunter, M, Santa Maria, L, Alliende, A, Slee, J, et al. Agreement between parents' and clinical researchers' ratings of behavioral problems in children with fragile X syndrome and chromosome 15 imprinting disorders.. Research in Developmental Disabilities 131: 104338 -104338 2022
    view publication
  • Arpone, M, Bretherton, L, Amor, DJ, Hearps, SJC, Rogers, C, Field, MJ, Hunter, MF, Santa Maria, L, Alliende, AM, Slee, J, et al. Agreement between parents' and clinical researchers' ratings of behavioral problems in children with fragile X syndrome and chromosome 15 imprinting disorders. Research in Developmental Disabilities 131: 104338 2022
    view publication
  • Kraan, CM, Date, P, Rattray, A, Sangeux, M, Bui, QM, Baker, EK, Morison, J, Amor, DJ, Godler, DE. Feasibility of wearable technology for ‘real‐world’ gait analysis in children with Prader–Willi and Angelman syndromes. Journal of Intellectual Disability Research 66(8-9) : 717 -725 2022
    view publication
  • Baker, EK, Merton, CF, Tan, W-H, Dudding-Byth, T, Godler, DE, Sadhwani, A. Methylation analysis and developmental profile of two individuals with Angelman syndrome due to mosaic imprinting defects. European Journal of Medical Genetics 65(4) : 104456 2022
    view publication
  • Godler, DE, Ling, L, Gamage, D, Baker, EK, Bui, M, Field, MJ, Rogers, C, Butler, MG, Murgia, A, Leonardi, E, et al. Feasibility of Screening for Chromosome 15 Imprinting Disorders in 16 579 Newborns by Using a Novel Genomic Workflow. JAMA Network Open 5(1) : e2141911 2022
    view publication

Page 1 of 12

Professional activities